Corvus Pharmaceuticals, Inc.
CRVS evidence brief
What we can confirm
- BioSniper Score:
- 8.8 / 10
- Market Cap:
- $1.12B
- Lead Asset:
- ciforadenant (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CRVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRVS
Corvus Pharmaceuticals is a clinical-stage biotech developing its oral ITK inhibitor soquelitinib across oncology and immune indications, with a Phase 3 PTCL trial and a Phase 1 atopic dermatitis trial ongoing.
Key risk: Single-asset dependency
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.12B
Cash Runway
—
Lead Asset
ciforadenant (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 5 clinical trials for Corvus Pharmaceuticals, Inc..
Corvus Pharmaceuticals is a clinical-stage biotech developing its oral ITK inhibitor soquelitinib across oncology and immune indications, with a Phase 3 PTCL trial and a Phase 1 atopic dermatitis trial ongoing.
- Cash & equivalents of $18.9M as of 2026-06-30 [sec].
- Net loss of $18.0M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $225.3M as of 2026-06-30 [sec].
- Lead asset soquelitinib is being tested in five different diseases, including a Phase 3 registrational trial in PTCL and a Phase 1 trial in atopic dermatitis [sec_mda · as of 2026-03-12].
- Cash runway expected to support operations into Q2 2028 [news · published 2026-08-10].
What works
- Soquelitinib is being studied across multiple indications (PTCL, atopic dermatitis, asthma, etc.), which diversifies pipeline risk [news · published 2026-08-17].
- The company has a Phase 3 registrational trial underway for soquelitinib in PTCL, a potential path to approval [sec_mda · as of 2026-03-12].
- Cash runway extends into Q2 2028, providing a multi-year operational buffer [news · published 2026-08-10].
What to weigh
- The company reported a net loss of $18.0M for the first half of 2026, with a Q1 2026 net loss of $13.69M [sec] [news · published 2026-05-10].
- Corvus is a single-asset biotech heavily reliant on soquelitinib, creating concentration risk [news · published 2026-08-17].
- A $46.16M shelf registration filed in May 2026 could lead to shareholder dilution [news · published 2026-05-10].
From the filings
Quoted directly from source documents.
Soquelitinib Phase 3 registrational trial in PTCL
“enrollment and completion of our ongoing Phase 3 registrational clinical trial for soquelitinib in PTCL”
SEC MD&A · March 12, 2026
Catalyst timeline
- 2024-04-16 · Phase 1 atopic dermatitis trial start — A Phase 1, randomized, blinded, placebo-controlled dose escalation/expansion study of soquelitinib in moderate-to-severe atopic dermatitis.
- 2024-10-02 · Phase 3 PTCL trial start — A Phase 3, randomized, open-label study of soquelitinib versus physician's choice in relapsed/refractory PTCL.
- 2026-02-01 · Phase 2 start (indication not fully specified in chunk) — A Phase 2 multicenter, randomized, double-blind, placebo-controlled study initiated.
Risks & what to watch (3)›
Key risks
- Single-asset dependency — Corvus is heavily reliant on soquelitinib; failure in one indication could severely impact the company. [news · published 2026-08-17]
- Net losses and cash burn — Net loss of $18.0M in H1 2026; Q1 2026 net loss of $13.69M. [sec] [news · published 2026-05-10]
- Potential dilution from shelf offering — A $46.16M shelf registration for ~2.99M shares was filed in May 2026. [news · published 2026-05-10]
What to watch
- Interim futility analysis for soquelitinib in PTCL expected in Q1 2027 [news · published 2026-08-10].
- Advancement of soquelitinib in atopic dermatitis, with Phase 1 completion planned [sec_mda · as of 2026-03-12].
- Cash runway into Q2 2028 and any changes in operating expenses [news · published 2026-08-10].
Sources: Catalysts · News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Corvus Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Corvus Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 24.9%
- Days to cover
- 14.9
- Shares short
- 18,385,941
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Corvus Pharmaceuticals, Inc.?
Corvus Pharmaceuticals is a clinical-stage biotech developing its oral ITK inhibitor soquelitinib across oncology and immune indications, with a Phase 3 PTCL trial and a Phase 1 atopic dermatitis trial ongoing.
What is Corvus Pharmaceuticals, Inc.'s lead drug candidate?
Corvus Pharmaceuticals, Inc.'s most advanced tracked candidate is ciforadenant (Phase 2) for metastatic RCC.
Who is the CEO of Corvus Pharmaceuticals, Inc.?
Dr. Richard A. Miller M.D. is the chief executive officer of Corvus Pharmaceuticals, Inc. (CRVS).
Where is Corvus Pharmaceuticals, Inc. headquartered?
Corvus Pharmaceuticals, Inc. (CRVS) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Corvus Pharmaceuticals, Inc. focus on?
Corvus Pharmaceuticals, Inc. develops therapies across Oncology, Immunology, Infectious Disease, Metabolic, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.